High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?

Abstract

Background Drug costs are increasing in Europe, and there is a heightened need to reduce pressure on healthcare systems. In 2017, oncology, autoimmune disease, and diabetes featured as the three highest therapy areas for drug spend in the EU-28. However, the absolute 1-year drug spend growth for diabetes did not feature within the ten fastest growing therapy areas. Objective This study explores the association between drug spend and disease burden in oncology, autoimmune disease, and diabetes in the EU-28. Methods Oncology, autoimmune disease and diabetes therapeutic areas were investigated using four methodologies. Historical and forecasted drug spend was analysed using the IQVIA MIDAS ® drug sales database. Clinical and economic burden was estimated from targeted literature reviews. Trend analyses compared changes in drug spend with clinical burden using the Global Burden of Disease tool as the epidemiological reference. Cost per quality-adjusted life-years (QALYs) from UK health technology assessments were compared to interpret the health economic value. Results Oncology had the highest historical drug spend and growth compared with autoimmune disease and diabetes. Total drug spend and growth in oncology is forecasted to exceed diabetes by twofold. Increasing oncology drug spend historically did not correspond with reductions in mortality and morbidity. Diabetes had the lowest drug spend and greatest QALY/€1000 spent benefit. Conclusion This study indicates that drug spend may not correlate to clinical burden across diseases. Future research could stimulate debate on whether more equitable drug funding may improve disease management.

Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013–2020)

“…We obtained the procurement data of six NAs from IQVIA's China Hospital Pharmacy Audit (CHPA), which collects medicines procurement data from health facilities with more than 100 beds in 31 provinces (including county hospitals in rural areas). IQVIA's datasets have been used for medical‐related studies worldwide 16–20 . We get access to the socioeconomic and epidemiological data of each province from Data Center of China Public Health Science, 21 China Health Statistics Yearbook, 22 and China Health Account Report 23…”

“…IQVIA's datasets have been used for medical-related studies worldwide. [16][17][18][19][20] We get access to the socioeconomic and epidemiological data of each province from Data Center of China Public Health Science, 21 China Health Statistics Yearbook, 22 and China Health Account Report. 23…”

Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades

“…We extracted the first international launch date and national launch dates of prescription drugs from the IQVIA (formerly IMS Health) Database for the following 30 European countries: Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom (UK). The dataset has been used for distantly related research before [5,18,19].…”

A Comparative Analysis of Mucus Immunomodulatory Properties from Seven Marine Gastropods from the Mediterranean Sea

“…Immune system dysregulation is often related to inflammatory diseases and chronic illnesses such as obesity, diabetes, cancer, rheumatoid arthritis, and neurodegenerative and autoimmune diseases [ 1 ]. Chronic inflammation might be a problem for human health, being the major cause of immune-mediated diseases such as bowel disease or type 1 diabetes mellitus [ 1 ], which in turn have a high cost for society [ 2 ]. In 2011, this has been estimated in the USA as being about $100 billion per year.…”